Avid Bioservices Inc (CDMO)

[jakedogman1]

Very frustrated. Talked with someone very close to company. Next 4 months should be worthwhile. Thorpe talk on Oct 30 good but not the big value driver. hep C repeat dose study is what will drive value. Combo therapy trial out of India will be other key driver. BP wants to see results. As well as investment banks and institutional investors. I will sit tight until then.